Medical marijuana may not be safe for epilepsy


Wednesday, 16 August, 2017

Medical marijuana may not be safe for epilepsy

Researchers investigating the effects of medical marijuana on epileptic patients have found it may adversely interact with antiepilectic drugs.

New research published in Epilepsia, a journal of the International League Against Epilepsy (ILAE), suggests that a neurological treatment derived from cannabis may alter the blood levels of commonly used antiepileptic drugs. It is important for clinicians to consider such drug interactions during treatment of complex conditions.

Cannabidiol (CBD), a compound developed from the cannabis plant, is being studied as a potential anticonvulsant and has demonstrated effectiveness in animal models of epilepsy and in humans. An ongoing open-label study (expanded access program) conducted by investigators at the University of Alabama at Birmingham is testing the potential of CBD as a therapy for children and adults with difficult-to-control epilepsy. The study includes 39 adults and 42 children, all of whom receive CBD.

Because all of the participants are also taking other seizure drugs while they are receiving the investigational therapy, investigators checked the blood levels of their other seizure drugs to see if they changed. “With any new potential seizure medication, it is important to know if drug interactions exist and if there are labs that should be monitored while taking a specific medication,” said lead author Dr Tyler Gaston.

Dr Gaston and her colleagues found that there were significant changes in levels of the drugs clobazam, topiramate and rufinamide in both adults and children, and zonisamide and eslicarbazepine in adults only. Except for clobazam/desmethylclobazam, however, the drug levels did not change outside of the normally accepted range. In addition, adult participants in the study taking clobazam more frequently reported sedation. 

Tests also showed that participants taking valproate and CBD had higher ALT and AST (liver function tests) compared with participants not taking valproate. Very high ALT and AST indicate abnormal liver function, but significant ALT and AST elevation occurred only in a small number of participants (four children and one adult), and the levels returned to normal after discontinuation of valproate and CBD.

“While the interaction between CBD and clobazam has been established in the literature, there are currently no published human data on CBD’s potential interactions with other seizure medications,” said Dr Gaston. “However, given the open-label and naturalistic follow-up design of this study, our findings will need to be confirmed under controlled conditions.”

The findings emphasise the importance of monitoring blood levels of antiepileptic drugs as well as liver function during treatment with CBD. “A perception exists that since CBD is plant based ... it is natural and safe; and while this may be mostly true, our study shows that CBD, just like other antiepileptic drugs, has interactions with other seizure drugs that patients and providers need to be aware of,” said Dr Gaston.

Image credit: ©iStockphoto.com/TerryLucas

Related News

Blood analysis could help predict sepsis in children

Professor Luregn Schlapbach from UQ's Child Health Research Centre said sepsis is best...

AI in health: CSIRO report highlights opportunities, challenges

The use of AI in health care is unique because the accuracy of models could mean the difference...

Study reports rise in use of 'designer' drug substitutes

An alert has been issued on the use of designer drug substitutes, following a 75% increase in...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd